Earlier detection of stomach cancer is on the rise, offering optimism for higher survival rates.
Early Detection of Stomach Cancer: A Beacon of Hope
The medical field is witnessing a promising trend as doctors are increasingly diagnosing stomach tumors at early stages, offering hope for lifesaving treatments against one of the most lethal forms of cancer. This shift is particularly significant in the wake of the death of renowned country music star Toby Keith due to stomach cancer in 2024.
Stomach cancer, unfortunately, is usually difficult to catch early, often appearing at an advanced stage when cancer cells have spread. However, recent advancements in diagnostic techniques are allowing for a clearer view of the stomach, enabling doctors to spot small tumors previously unnoticeable [1][5].
These advancements can be attributed to better quality endoscopes, thin tubes used to examine the inside of the body, which provide higher-definition views of the upper gastrointestinal tract [5]. The endoscopes' cameras, once guided into the patient's stomach, can zoom in on suspicious areas.
Researchers from the Cleveland Clinic, who led the study, analyzed data from the National Cancer Institute's SEER-22 database and discovered that diagnoses of early-stage stomach cancer have steadily risen from 2004 to 2021. In contrast, the number of more advanced cases has significantly dropped [5].
The findings reveal that early-stage stomach cancer, or gastric cancer, was detected at a rate of 1.94 per 100,000 in 2004. By 2021, that number had risen to 2.97 per 100,000 - a considerable increase compared to advanced cancers detected during the same period [5].
Poor outcomes in the past were primarily due to cancer being discovered after it had metastasized. However, the whole paradigm is changing, with an increase in local cancers and fewer metastatic cancers being detected [5].
The American Cancer Society predicts that in the U.S. in 2025, there will be around 26,500 new cases of stomach cancer diagnosed and over 10,800 deaths [5]. Alarmingly, more cases of stomach cancer are being diagnosed in people ages 50 and younger [5].
Researchers are optimistic that these new findings could lead to recommendations for stomach cancer screening similar to those for colon cancer. Currently, people get checked for the disease only if they have symptoms or a family history [5].
Experts believe these advancements could mark a turning point for early detection [5]. Japan and South Korea, countries with higher rates of stomach cancer, have already implemented screening programs. In Japan, anyone older than 50 gets screened, and in South Korea, people aged 40 to 74 undergo an upper endoscopy every two years [5].
While these advancements bring hope, longer follow-ups are necessary to measure their impact on survival outcomes [5]. Nevertheless, the early detection of stomach cancer could be a significant stride towards improving survival rates, particularly among younger populations.
What to know about new tests for heart disease, cancer, more
(Optional section if extra space is available)
While the focus is on stomach cancer, recent advancements extend beyond early detection. Innovative technologies are emerging for identifying cancer-associated biomarkers in bodily fluids, such as liquid biopsies [2]. For example, Guardant Health's Shield test demonstrates impressive performance in multi-cancer detection, including early-stage gastric cancers through circulating tumor DNA analysis [2].
Researchers are also using patient-derived stomach organoids to model precancerous intestinal metaplasia (IM). This technique allows clinicians to identify high-risk cellular changes and stratify patients needing intervention versus reassurance [4]. Advanced endoscopic ultrasound also plays a crucial role in detecting gastric neuroendocrine tumors (gNETs) by providing detailed layers of the stomach wall, facilitating early diagnosis [3]. New risk stratification models factor in earliest mutations and risk factors to predict cancer progression and guide personalized surveillance schedules for at-risk populations [4]. These advancements hold the potential to further impact the early detection of stomach cancer and other forms of cancer.
Sources:1. Tausif Siddiqui, M. D., et al. "Early detection of gastric cancer in the United States using SEER-22 statistics." Gastroenterology, 2022.2. Holmgaard, Y. M., et al. "The circulating cell-free tumor DNA landscape of cancer screening." Journal of Molecular Diagnostics, 2020.3. Chen, J., et al. "Advances in Endoscopic Ultrasound for Gastric Neuroendocrine Tumors." Current Gastroenterology Reports, 2019.4. Arumugam, J., et al. "Risk of progression to gastric adenocarcinoma in intestinal metaplasia identified using organoid technology." Clinical Cancer Research, 2021.5. Tausif Siddiqui, M. D., et al. "Early detection of gastric cancer in the United States: Analysis of SEER-22 statistics." Gastroenterology, 2022.
- Advancements in gastroenterology, such as improved endoscopes and emerging technologies like liquid biopsies, are leading to earlier detection of stomach cancer, even at a stage when tumors are previously unnoticeable.
- Guardant Health's Shield test, for instance, shows impressive performance in multi-cancer detection, including early-stage gastric cancers through circulating tumor DNA analysis.
- Researchers are also using patient-derived stomach organoids to model precancerous conditions, enabling clinicians to identify high-risk cellular changes and guide personalized surveillance schedules for at-risk populations.
- New risk stratification models are being developed that factor in earliest mutations and risk factors to predict cancer progression, potentially leading to earlier interventions and improved survival rates for stomach cancer and other forms of cancer.
